TY  - CONF

T1  - 52-week laboratory safety findings from an open-label extension (OLE) study of dupilumab in adolescent patients with atopic dermatitis (LIBERTY AD PED-OLE)

JO  - JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

PY  - 2021/01/01

AU  - Cork MJ

AU  - Lockshin B

AU  - Blauvelt A

AU  - Chen Z

AU  - Khokhar FA

AU  - Bansal A

AU  - Prescilla R

ED  - 

VL  - 85

IS  - 3

SP  - AB120

EP  - AB120

Y2  - 2024/12/22

ER  -